scholarly journals Colour Me Blue: The History and the Biotechnological Potential of Pyocyanin

Molecules ◽  
2021 ◽  
Vol 26 (4) ◽  
pp. 927
Author(s):  
Thiago Gonçalves ◽  
Ulrich Vasconcelos
Keyword(s):  
Pseudomonas Aeruginosa ◽  
Antibiotic Therapy ◽  
Electric Current ◽  
Antimicrobial Therapy ◽  
Blue Colour ◽  
Current Generation ◽  
Biotechnological Potential ◽  
Avant Garde ◽  
New Horizons ◽  
The Subject

Pyocyanin was the first natural phenazine described. The molecule is synthesized by about 95% of the strains of Pseudomonas aeruginosa. From discovery up to now, pyocyanin has been characterised by a very rich and avant-garde history, which includes its use in antimicrobial therapy, even before the discovery of penicillin opened the era of antibiotic therapy, as well as its use in electric current generation. Exhibiting an exuberant blue colour and being easy to obtain, this pigment is the subject of the present review, aiming to narrate its history as well as to unveil its mechanisms and suggest new horizons for applications in different areas of engineering, biology and biotechnology.

scholarly journals Outpatient Parenteral Antimicrobial Therapy With Ceftolozane/Tazobactam via Continuous Infusion for Multidrug-Resistant Pseudomonas aeruginosa Osteomyelitis

2020 ◽  
Vol 7 (11) ◽  
Author(s):  
Judith Álvarez Otero ◽  
Jose Luis Lamas Ferreiro ◽  
Ana Sanjurjo Rivo ◽  
Javier de la Fuente Aguado
Keyword(s):  
Pseudomonas Aeruginosa ◽  
Antibiotic Therapy ◽  
Continuous Infusion ◽  
Antimicrobial Therapy ◽  
Multidrug Resistant ◽  
Effective Alternative ◽  
Outpatient Parenteral Antimicrobial Therapy ◽  
At Home

Abstract We present a case of Pseudomonas aeruginosa osteomyelitis treated with surgery and antibiotic therapy with ceftolozane-tazobactam in continuous infusion at home using an elastomeric pump. We discuss the use of ceftolozane-tazobactam in continuous infusion administered at home as an effective alternative for the treatment of multidrug-resistant Pseudomonas aeruginosa osteomyelitis.

Quorum sensing regulates electric current generation of Pseudomonas aeruginosa PA14 in bioelectrochemical systems

2010 ◽  
Vol 12 (3) ◽  
pp. 459-462 ◽  
Author(s):  
Arvind Venkataraman ◽  
Miriam Rosenbaum ◽  
Jan B.A. Arends ◽  
Rayko Halitschke ◽  
Largus T. Angenent
Keyword(s):  
Pseudomonas Aeruginosa ◽  
Quorum Sensing ◽  
Electric Current ◽  
Bioelectrochemical Systems ◽  
Current Generation

Identification of Optimal Combinations for Empirical Dual Antimicrobial Therapy of Pseudomonas aeruginosa Infection: Potential Role of a Combination Antibiogram

2006 ◽  
Vol 27 (4) ◽  
pp. 413-415 ◽  
Author(s):  
Mari Mizuta ◽  
Darren R. Linkin ◽  
Irving Nachamkin ◽  
Neil O. Fishman ◽  
Mark G. Weiner ◽  
...  
Keyword(s):  
Pseudomonas Aeruginosa ◽  
Antibiotic Therapy ◽  
Antimicrobial Therapy ◽  
Potential Role ◽  
Drug Combinations ◽  
Fine Tuning ◽  
Pseudomonas Aeruginosa Infection

To better determine the optimal combinations for empirical dual antimicrobial therapy of Pseudomonas aeruginosa infection, we evaluated the utility of a novel combination antibiogram. Although the combination antibiogram allowed modest fine-tuning of choices for dual antibiotic therapy, selections based on the 2 antibiograms did not differ substantively. Drug combinations with the broadest coverage were consistently composed of an aminoglycoside and a β-lactam.

scholarly journals Risk Factors for Mortality among Patients with Pseudomonas aeruginosa Bloodstream Infections: What Is the Influence of XDR Phenotype on Outcomes?

2020 ◽  
Vol 9 (2) ◽  
pp. 514
Author(s):  
María Milagro Montero ◽  
Inmaculada López Montesinos ◽  
Hernando Knobel ◽  
Ema Molas ◽  
Luisa Sorlí ◽  
...  
Keyword(s):  
Risk Factors ◽  
Pseudomonas Aeruginosa ◽  
High Risk ◽  
Antibiotic Therapy ◽  
Antimicrobial Therapy ◽  
Protective Factor ◽  
Bloodstream Infections ◽  
Clinical Severity ◽  
Risk Source ◽  
The Impact

This study aimed to assess the impact of extensively drug-resistant (XDR) phenotype on mortality in Pseudomonas aeruginosa bacteremia. A retrospective cohort study was performed in a tertiary hospital from January 2000 to December 2018. All consecutive prospectively recorded P. aeruginosa bacteremia in adult patients were assessed. In this study, 382 patients were included, of which 122 (31.9%) due to XDR P. aeruginosa. Independent factors associated with 14-day mortality were as follows: high-risk source of bacteremia (hazard ratio (HR) 3.07, 95% confidence interval (CI), 1.73–5.46), septic shock (HR 1.75, 95% CI, 1.12–2.75), and higher Pitt scores (one-point increments; HR 1.25, 95% CI, 1.12–1.38). Otherwise, the appropriateness of definitive antibiotic therapy was a protective factor (HR 0.39, 95% CI, 0.24–0.62). The same variables were also associated with 30-day mortality. XDR phenotype was not associated with 14- or 30-day mortality. In a subanalysis considering only high-risk source cases, combined antimicrobial therapy was independently associated with 14-day favorable outcome (HR 0.56, 95% CI, 0.33–0.93). In conclusion, XDR phenotype was not associated with poor prognosis in patients with P. aeruginosa bacteremia in our cohort. However, source of infection, clinical severity, and inappropriate definitive antibiotic therapy were risk factors for mortality. Combined antimicrobial therapy should be considered for high-risk sources.

CP-126 Analysis of antimicrobial therapy used to treat pseudomonas aeruginosa bacteraemia

2016 ◽  
Vol 23 (Suppl 1) ◽  
pp. A55.2-A56
Author(s):  
E Sanchez-yañez ◽  
E Aguilar ◽  
G Ojeda ◽  
JM Fernández-Ovies
Keyword(s):  
Pseudomonas Aeruginosa ◽  
Antimicrobial Therapy
Sign in / Sign up

Export Citation Format

Share Document